Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Surrogate Of A Surrogate' Not Good Enough For Raxone Accelerated Approval

Executive Summary

FDA’s decision to require second pre-approval trial for Santhera’s DMD candidate is just latest example of the inability of rare disease treatments with surrogate endpoints to qualify for pathway.

You may also be interested in...



Inside A Phase III Disappointment: Santhera Reduced Target Population, Now Needs Another Trial

FDA seemed on board with Swiss drugmaker's plans for study of Duchenne muscular dystrophy candidate Raxone, but didn't look too kindly on firm's decision to drop subjects using concomitant glucocorticoids.

Santhera Setback Could Have Wide-Reaching Effects For DMD Drugs

The DMD community faces another setback as FDA pushes back timelines for Santhera and its respiratory drug, pushing the market to question what will come for other DMD treatments in development.

Patients Can't Rescue Sarepta's Eteplirsen

Hours of testimony was clearly compelling, but advisory committee agreed with FDA concerns about the Duchenne muscular dystrophy drug's efficacy.

Topics

UsernamePublicRestriction

Register

PS118774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel